Study guide
7.4 Phase II Biotransformation: Conjugation Pathways, Bioactivation & Detoxification
DABT: Diplomate of the American Board of Toxicology Exam
Track your progress as you read
Finished sections get a check mark.
1 Exam Overview & Study Design Fundamentals
1.1 Current DABT Exam Facts 1.2 Study Objectives, Hypothesis Testing & Regulatory Guideline Selection 1.3 Test System Selection, Species Models & Animal Welfare (3Rs, IACUC) 1.4 Route Selection, Dosing Regimens & Treatment Duration
2 Dose Selection, Controls & Biostatistics in Toxicology
2.1 Dose Selection Strategies: Range-Finding, Maximum Tolerated Dose (MTD) & Limit Doses 2.2 Control Groups (Negative, Vehicle, Positive, Sham) & Confounding Factors 2.3 Statistical Design, Power Analysis & Statistical Testing of Toxicological Data
3 Study Execution, GLP Compliance & Quality Assurance
3.1 Good Laboratory Practice (GLP) Regulations (FDA 21 CFR Part 58, OECD GLP) & Study Director Responsibilities 3.2 Test Article Characterization, Formulation Analysis, Stability & Homogeneity 3.3 Standard Operating Procedures (SOPs), Quality Assurance Unit (QAU) & Audit Inspections
4 Executing In Vivo, In Vitro, In Silico & Field Studies
4.1 In-Life Clinical Signs, FOB, Body Weight, Food/Water, Ophthalmology 4.2 In Vitro, In Silico (QSAR, Read-Across, PBPK, AI/ML), Field, Clinical & Epidemiologic Characterization
5 Clinical Pathology & Toxicologic Pathology
5.1 Hematology & Coagulation Parameters in Safety Evaluation 5.2 Clinical Chemistry: Biomarkers of Hepatic, Renal & Muscle Injury 5.3 Urinalysis & Specialized Biomarkers of Organ Toxicity 5.4 Toxicologic Pathology: Organ Weights, Gross Necropsy & Histopathology Interpretation
6 Specialized Toxicological Study Endpoints
6.1 Genetic Toxicology Assays: Ames Test, Chromosomal Aberrations & Micronucleus Assays 6.2 Reproductive & Developmental Toxicity Testing (ICH S5, Segments I, II, III) 6.3 Carcinogenicity Bioassays: Design, Conduct & Neoplastic Lesion Evaluation 6.4 Safety Pharmacology (Core Battery: Cardiovascular/hERG, CNS, Respiratory) & Immunotoxicology
7 Toxicokinetics & Biotransformation
7.1 Absorption & Physiological Barriers (Membrane Transport, Blood-Brain Barrier, GI Absorption) 7.2 Distribution, Plasma Protein Binding & Transporters (P-gp, OATs, OCTs, BSEP) 7.3 Phase I Biotransformation: Cytochrome P450 Monooxygenases & Non-CYP Oxidation 7.4 Phase II Biotransformation: Conjugation Pathways, Bioactivation & Detoxification
8 Cellular Mechanisms of Toxicity & Organ Pathogenesis
8.1 Oxidative Stress, Reactive Oxygen/Nitrogen Species (ROS/RNS) & Antioxidant Defenses 8.2 Cell Death Pathways: Necrosis, Apoptosis, Autophagy & Mitochondrial Dysfunction 8.3 Molecular Mechanisms of Target Organ Toxicity: Hepatotoxicity, Nephrotoxicity & Neurotoxicity
9 Hazard Identification & Evidence Integration
9.1 Hazard Identification Principles, Weight of Evidence (WoE) & Systematic Review 9.2 Carcinogen Hazard Classification Schemes (IARC, EPA Guidelines, GHS) 9.3 Agent Classes & Organ-System Toxic Responses
10 Mode of Action, AOPs & Non-Cancer Endpoints
10.1 Mode of Action (MoA) Framework & Human Relevance Evaluation 10.2 Adverse Outcome Pathways (AOP): Molecular Initiating Events, Key Events & Organ-Level Outcomes 10.3 Non-Cancer Systemic Toxicity Endpoints & Target Organ Critical Effects
11 Exposure Assessment Methodologies & Quantification
11.1 Exposure Routes, Scenarios & Pathways (Occupational, Dietary, Environmental, Consumer) 11.2 Exposure Quantification: Dose Equations, Average Daily Dose (ADD) & Lifetime Average Daily Dose (LADD) 11.3 Inhalation Dosimetry: Human Equivalent Concentrations (HEC) & Regional Gas Dose Ratios (RGDR) 11.4 Biomonitoring, Internal Dose, Fate/Transport & BCF
12 Quantitative Dose-Response Principles & Point of Departure Derivation
12.1 Dose-Response Relationships: Threshold vs Non-Threshold, Linear vs Non-Linear Models 12.2 Point of Departure (PoD) Determination: NOAEL, LOAEL & Benchmark Dose (BMD/BMDL) Modeling 12.3 Low-Dose Extrapolation, Cancer Slope Factors (CSF), Unit Risk & First-in-Human Dose
13 Health-Based Guidance Value Derivation & Uncertainty Factors
13.1 Uncertainty Factors (UFs), Interspecies/Intraspecies Extrapolation & Chemical-Specific Adjustment Factors (CSAF) 13.2 Derivation of Reference Values: RfD, RfC, ADI, TDI & Permissible Daily Exposure (PDE)
14 Risk Characterization for Non-Cancer & Cancer Health Effects
14.1 Non-Cancer Risk Characterization: Hazard Quotient (HQ), Hazard Index (HI) & Margin of Exposure (MoE) 14.2 Cancer Risk Characterization: Excess Lifetime Cancer Risk & Acceptable Risk Tolerances 14.3 Uncertainty & Sensitivity Analysis in Risk Characterization
15 Risk Management, Occupational Exposure Limits & Environmental Standards
15.1 Occupational Exposure Limit (OEL) Derivation: OSHA PELs, ACGIH TLVs & NIOSH RELs 15.2 Environmental Quality Standards: Drinking Water MCLs & Air Quality Standards (NAAQS) 15.3 Risk Management Decision-Making, Risk Communication & Socioeconomic Considerations
16 Regulatory Frameworks & Product Stewardship
16.1 Food, Drug & Cosmetic Regulation: FDA Framework, Delaney Clause & GRAS Evaluations 16.2 Chemical Substances & Environmental Regulation: EPA TSCA, FIFRA, Clean Air & Clean Water Acts 16.3 International Regulatory Harmonization: OECD, ICH Guidelines & EU REACH
17 Clinical Toxicology & Medical Management of Poisoning
17.1 Clinical Toxidromes & Initial Management of Acute Poisoning 17.2 Specific Antidotes, Mechanisms of Action & Decontamination Strategies
18 Environmental, Ecological & Public Health Toxicology
18.1 Environmental Toxicology: Fate, Transport, Bioaccumulation (log Kow, BCF) & Ecotoxicological Testing 18.2 Public Health Events, Epidemiology, Susceptible Subpopulations & Exposure Investigation
7.4 Phase II Biotransformation: Conjugation Pathways, Bioactivation & Detoxification
Key Takeaways Explain This Topic AI
UGT, SULT, GST, NAT, amino-acid conjugation, and methylation attach cofactors (UDP-glucuronic acid, PAPS, GSH, acetyl-CoA, glycine/taurine, SAM) that usually increase excretability—but some conjugates are more reactive than parent.
Acetaminophen: most of a therapeutic dose is glucuronidated or sulfated; CYP2E1 (with 1A2/3A4) forms NAPQI, which GST conjugates to GSH; GSH depletion allows covalent protein binding and centrilobular necrosis; N-acetylcysteine restores GSH.
Carbon tetrachloride yields a CYP2E1-derived trichloromethyl radical; aflatoxin B1 yields an 8,9-epoxide that adducts N7-guanine unless GST intercepts it; benzo[a]pyrene becomes a bay-region diol epoxide (BPDE) via CYP plus epoxide hydrolase.
Cats have a UGT1A6 pseudogene and glucuronidate many phenols poorly, which is why acetaminophen is so dangerous in felines; Crigler-Najjar syndrome is a human UGT1A1 deficiency with severe unconjugated hyperbilirubinemia.
NAT2 slow acetylation is a human susceptibility trait; dogs remain the laboratory species that poorly N-acetylates many aromatic amines—keep that distinct from feline UGT loss.
Last updated: September 2026
Conjugation as the fork between excretion and covalent binding
Phase I often creates a nucleophilic or electrophilic handle. Phase II attaches a cofactor that usually makes the product more polar and a substrate for MRP2, OATs, or biliary/renal excretion . The same chemistry can instead yield a better electrophile (sulfate esters of N-hydroxy aromatic amines; some acyl glucuronides; epoxides that escape GST). Independent ExamFinch teaching in this Domain II.2 section covers the major human conjugation paths, glutathione as a depletable defense, three textbook bioactivations ( CCl4 , aflatoxin B1 , benzo[a]pyrene ), and conjugation capacity defects in cats and in Crigler-Najjar disease. It is not an ABT product and does not claim official approval, review, or partnership with ABT.
Keep the fork in mind for every parent: Phase I reactive intermediate → Phase II conjugate and excretion , versus covalent binding to protein or DNA when the intermediate outruns conjugation.
UGT, SULT, GST, NAT, amino acids, methylation
UDP-glucuronosyltransferases (UGTs) in the ER transfer glucuronic acid from UDP-glucuronic acid to phenols, alcohols, carboxylic acids, and amines. Products are organic anions exported by MRP2 and related pumps. UGT1A1 glucuronidates bilirubin . UGT1A6 glucuronidates many simple phenols and a large share of acetaminophen in humans. Acyl glucuronides of some carboxylic acids can rearrange and bind protein—an uncommon but real bioactivation.
Sulfotransferases (SULTs) in cytosol transfer sulfonate from PAPS . Sulfation is often high affinity, low capacity : it saturates before glucuronidation at overdose. SULT can detoxify phenols or bioactivate N-hydroxy arylamines by forming sulfate esters that leave a nitrenium ion .
Glutathione-S-transferases (GSTs) conjugate glutathione (GSH) to electrophiles (epoxides, NAPQI, many unsaturated carbonyls). Products are processed to mercapturic acids and excreted. GSTM1-null genotypes are common and are discussed as susceptibility modifiers for some epoxide-forming carcinogens. GSH is a finite pool: synthesis via γ-glutamylcysteine ligase can be outrun; N-acetylcysteine supplies cysteine.
N-acetyltransferases (NAT1, NAT2) transfer acetyl from acetyl-CoA to aromatic amines and hydrazines. NAT2 slow acetylators accumulate isoniazid and some arylamines. Dogs remain poor acetylators (7.3); humans are not.
Amino-acid conjugation (often mitochondrial) activates a carboxylic acid as an acyl-CoA, then links glycine (benzoate → hippurate ), taurine , or glutamine. It is a detoxification path for some aromatic acids and a competitor for CoA.
Methylation uses S-adenosylmethionine (SAM) : COMT , TPMT (thiopurines—another polymorphism), PNMT , AS3MT (arsenic). Methylation does not always increase water solubility; it often reduces receptor activity. Arsenic methylation is a mixed toxicologic story (some methylated species remain highly toxic).
Acetaminophen: NAPQI, GSH, and centrilobular necrosis
At therapeutic doses, most acetaminophen is glucuronidated (UGT) or sulfated (SULT) and excreted in urine. A minority is oxidized by CYP2E1 , with contributions from CYP1A2 and CYP3A4 , to N-acetyl-p-benzoquinone imine (NAPQI) . GST conjugates NAPQI to GSH. When the dose is large, sulfate capacity saturates, more parent reaches CYPs, GSH falls , and NAPQI covalently binds cysteines on hepatocellular proteins , injuring mitochondria. Necrosis is centrilobular (zone 3), where CYP2E1 is richest and oxygen tension favors some bioactivation patterns. N-acetylcysteine works if given while hepatocytes can still synthesize GSH and before massive necrosis. Ethanol induction of CYP2E1 plus fasting (less GSH) worsens the risk after the ethanol is gone; simultaneous ethanol can compete at CYP2E1. Cats skip much of the UGT safety net (below), so the same milligram-per-kilogram is a different internal-dose problem.
Three bioactivation archetypes
Carbon tetrachloride. CYP2E1 catalyzes reductive dehalogenation to the trichloromethyl radical (•CCl3) , which adds oxygen to form trichloromethylperoxy radical . The radicals drive lipid peroxidation , break calcium homeostasis, and kill centrilobular hepatocytes. Phenobarbital or ethanol induction of CYPs can worsen CCl4 injury; hypoxia in zone 3 favors the reductive path. GSH and other antioxidants modulate, but this is a radical story more than a stable epoxide story.
Aflatoxin B1. Hepatic CYP3A4 and CYP1A2 form AFB1-8,9-epoxide . The exo-epoxide binds N7-guanine , producing a promutagenic adduct implicated in hepatocellular carcinoma , especially with chronic hepatitis B. GST conjugation of the epoxide is a major detoxification; epoxide hydrolase also contributes. Species and human GST differences help explain why trout, rats, and humans do not share identical AFB1 potency.
Benzo[a]pyrene. CYP1A1/1B1 (AhR-inducible) form an epoxide; microsomal epoxide hydrolase yields the 7,8-dihydrodiol ; a second CYP oxidation creates the bay-region 7,8-diol-9,10-epoxide (BPDE) . BPDE adducts DNA (notably N2-guanine). GST and further conjugation compete with adduction. Note the double-edged hydrolase: the diol is on the path to the ultimate electrophile, not always a dead-end detox.
Cats, UGT1A6, and Crigler-Najjar as capacity lessons
Domestic cats carry UGT1A6 as a pseudogene and express a narrower UGT repertoire , so they glucuronidate many phenolic drugs poorly (acetaminophen, some other phenols; propofol handling is also unfavorable). More parent is shunted to oxidation and to pathways that produce methemoglobin and hepatic injury . This is a conjugation-capacity species difference, not a proof that cats lack CYP2E1.
Crigler-Najjar syndrome is a human UGT1A1 deficiency: unconjugated bilirubin cannot be glucuronidated efficiently, producing severe jaundice and kernicterus risk in the complete (type I) form. Gilbert syndrome is a milder UGT1A1 promoter variant. Neither disease means the patient is a cat. The shared lesson is: if the conjugating enzyme is missing, a normally “detox” substrate becomes a toxic parent . Use Crigler-Najjar to remember UGT1A1/bilirubin; use feline UGT1A6 to remember phenols and acetaminophen.
Pathway Cofactor Detoxification example Bioactivation / capacity trap
UGT UDP-glucuronic acid APAP glucuronide; bilirubin (UGT1A1) Acyl glucuronides; cat UGT1A6 loss; Crigler-Najjar
- SULT PAPS Phenol sulfates at low dose Nitrenium ions from N-hydroxy arylamine sulfates; low capacity
- GST GSH NAPQI-SG; AFB1-epoxide-SG; BPDE-SG GSH depletion unmasks covalent binding
- NAT Acetyl-CoA Isoniazid acetylation in rapid acetylators Slow NAT2; dogs poor acetylators
- Amino-acid Acyl-CoA + glycine/taurine Benzoate → hippurate CoA sequestration at huge doses
- Methylation SAM Many catechols (COMT); TPMT on thiopurines Some methylated arsenicals remain toxic
- Realistic scenario
A 24-hour mouse APAP study shows centrilobular necrosis, collapsed hepatic GSH, and APAP-protein adducts. Co-administration of NAC 1 hour after APAP reduces adducts and necrosis; a CYP2E1 inducer (chronic ethanol, then a dry interval) worsens them. That package is NAPQI outrunning GST , not NAT2 acetylation and not BSEP cholestasis. A second file: dietary AFB1 in a species with low hepatic GST toward the 8,9-epoxide produces high N7-guanine adducts— bioactivation minus conjugation . A third: a cat that received a “human pediatric” acetaminophen dose; calling it a CYP2D6 polymorphism case misses the UGT1A6 species defect.
Traps
Treating every Phase II product as automatically less toxic than parent.
Forgetting that epoxide hydrolase can sit on the path to BPDE.
Equating Crigler-Najjar (UGT1A1/bilirubin) with feline UGT1A6 (phenols).
Calling CCl4 injury an aflatoxin-style DNA-epoxide story.
Using dog acetylation deficiency to explain cat acetaminophen poisoning.